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Background: Nigeria has the second highest number of new HIV infections annually. Therefore, it is important to
explore new strategies for preventing new infections. The introduction of pre-exposure prophylaxis (PrEP) for use by
persons at high risk of HIV infection has new potential in preventing new HIV infections. The aim of this study is to
explore the public opinion, community interest, and perceptions about the use and access to PrEP in Nigeria.
Methods: This formative study used a mixed method approach to collect data on public opinions and perceptions on
appropriate target groups for PrEP access, community interest, perceptions about the use of PrEP as an HIV-prevention
tool, how best to communicate with participants about PrEP, concerns about PrEP use by serodiscordant couples, and
suggestions for the design and implementation of a PrEP demonstration project. Telephone and in-depth interviews
were conducted, and focus group discussions and consultative meetings were held with critical stakeholders engaged
in HIV-prevention, treatment, care, and support programmes in Nigeria. An online survey was also conducted.
Results: HIV serodiscordant couples were identified as the appropriate target group for PrEP use. Most respondents
felt that PrEP use by key affected populations would help reduce the HIV incidence. Stigma was identified as a major
concern and a potential barrier for the acceptance and use of PrEP by HIV serodiscordant couples. Electronic and print
media were identified as important means for massive public education to prevent stigma and create awareness about
PrEP. In a male dominated society such as Nigeria, HIV-negative male partners in serodiscordant relationships may
resist enrolment in PrEP programmes. This may be complicated by the fact that the identified index partner in most
serodiscordant relationships in Nigeria is an HIV-positive woman, who is often diagnosed during pregnancy.
Conclusions: PrEP uptake and use by HIV serodiscordant couples in Nigeria may face notable but surmountable
challenges. Much depends on the appropriateness of actions taken by multiple players. Motivation of HIV-negative male
partners to use PrEP and establishment of effective public education programmes in addressing stigma are essential.
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Access to treatment for people living with HIV has
improved in Nigeria in recent years. However, the pace of
expansion remains slow and is far from meeting the
universal target [1]. Nigeria has the second highest
number of new HIV infections annually [2], and prevention* Correspondence: toyinukpong@yahoo.co.uk
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unless otherwise stated.efforts have yet to significantly slow the epidemic. Unless
the influx of new infections is slowed, the Nigerian
government will be less able to assist people in need,
and AIDS will continue to devastate individuals, families,
communities, and nations.
Owing to these concerns and the shift in the focus of
HIV and AIDS management from a short-term emergency
to a long-term concern, recent years have witnessed a
renewed commitment by the Nigerian government to
HIV prevention. This commitment is increasingly focused
on developing new biomedical, behavioural, and structuralhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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menting proven approaches in combination that are
tailored to specific epidemiological and social contexts.
Large-scale clinical trials evaluating the use of antiretro-
viral drugs for HIV prevention have shown success [3-7]
and elated the HIV-prevention field. Still, the impact of
proven interventions may vary among locales because the
HIV epidemic differs geographically. A 2010 antenatal
sentinel survey in Nigeria showed a national HIV
prevalence of 4.1%, ranging between 2.0% and 10.0%
in various states. The HIV prevalence is generally higher
in urban areas (4.8%) than in rural areas (2.6%), though
the HIV prevalence is up to 21.3% in some rural
areas [8]. Although the 2012 national HIV household
survey showed a mean HIV prevalence of 3.1% [9], there
are variations within the population. For instance, HIV
prevalence among non-brothel based female sex workers
(FSW) was 27.4%, compared with 17.2% in men who have
sex with men (MSM) and 4.2% in people who inject drugs
(PWID) [10].
Even within communities, the prevalence differs. For
example, within the PWID community, women are
seven to 33 times more likely to be HIV-positive than
men [11]. Among diagnosed HIV serodiscordant couples
in Nigeria [12-14], women have an approximately 11 times
greater risk of being HIV-positive than HIV-negative [14].
The high incidence of HIV serodiscordance among
couples increases the risk of HIV transmission to the
HIV-negative partner unless concerted HIV-prevention
efforts are taken.
Women and girls are particularly vulnerable as the
existing HIV-prevention tools are not well suited for
their control. Current economic hardships force many
spouses to work away from home for long periods, and
there is little guarantee that monogamy is reciprocated
by the male partner in marital or stable relationships.
Gender norms condoning multiple sexual partnerships for
men exacerbate this and consequently increase women’s
vulnerability. Furthermore, male and female condoms,
which are the most commonly promoted risk-reduction
strategy, require that male partners elect or agree to use
them. This makes condoms potentially useless as an
HIV-prevention strategy in situations of rape and sexual
violence. Pre-exposure prophylaxis (PrEP) oral medication
can be used by women–covertly if desired–making them
an important addition to the HIV-prevention toolkit.
Considering these realities, it is important that Nigeria
apply new combinations of proven and mutually reinfor-
cing biomedical, behavioural, and structural interventions
through an iterative process. These strategies include the
use of PrEP, which holds promise in protecting many of
the most vulnerable and at-risk populations, including the
HIV-negative partners in serodiscordant partnerships,
MSM, sex workers, women, and girls. Therefore, it iscritical to explore the feasibility of PrEP use in combination
with other prevention strategies to address the HIV
epidemic in Nigeria, particularly in key target groups.
This formative study was conducted to explore public
opinions on PrEP including community interest and
perceptions its use as part of the HIV-prevention
armamentarium in Nigeria. Specifically, this formative
study sought to identify the appropriate study population
for recruitment in a potential PrEP demonstration project
by surveying public opinion, community interest, and per-
ception about the use of PrEP as part of HIV prevention
in Nigeria and to explore how best to discuss PrEP with
various stakeholders before, during, and after the pro-
posed PrEP demonstration project. This information will
inform the design and implementation of a subsequent
PrEP demonstration project in Nigeria.
A critical social ecological perspective was chosen for
this study [15,16]. Social ecological perspectives posit
that individual behaviours, such as intention to use
and adhere to antiretrovirals (ARVs), are influenced
by individual characteristics, interpersonal relationships,
and macro-level factors. Individuals adapt themselves and
their HIV-related behaviours to proximal and distal social
contexts and structures, while simultaneously, these
multiple social systems are affected by individual behav-
iours. We examined the potential of use of PrEP at both
an individual (serostatus, attitudes, perceived efficacy) and
structural (cultural norms, stigma, institutionalized dis-
crimination, legal structures, policy environments) level.
Methods
Study design
This was an exploratory descriptive study and was not
designed to test a hypothesis. The study objectives were
devised assuming that understanding the factors effecting
the adoption and use of PrEP as an HIV-prevention tool
will help in designing effective programmes in communities
targeted for intervention. We used a mixed method
approach that included telephone interviews; in-depth
interviews (IDIs); focus group discussions (FGDs); consulta-
tive meetings with critical stakeholders in HIV prevention,
treatment, care, and support programmes in Nigeria; and
an online survey to explore opinions on the design of
a future PrEP demonstration project in Nigeria. This
preliminary study was conducted between 30 October,
2013, and 4 February, 2014.
Study setting
Quantitative studies were conducted in the proposed
sites for a future PrEP clinical study as follows: Abuja
(Federal Capital Territory), Edo, Cross River, and Benue
states. Benue, Edo, and Cross-River states were proposed
as sites for a future PrEP demonstration project owing
to their high HIV prevalence [8]. Stakeholders engaged
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in Abuja; therefore, the state was also included as a study
setting. Data were also collected from participants outside
of these specific study sites through an online survey.
Study participants
Key stakeholders aged 18 years older who were involved
in the design and implementation of HIV-prevention
and treatment research, programmes, and policies in
Nigeria for at least 12 months were recruited to participate
in the telephone and IDIs. Among eligible individuals were
representatives of the Federal and State Ministry of Health,
Federal Health Parastatals, and the National and State
Agencies for the Control of AIDS (NACA); National HIV
Prevention and Treatment Technical Working Group
members; donor organizations and implementing partners;
HIV-prevention and treatment researchers; ethicists and
members of health research ethics committees; public
health officials, health care providers, and administrators,
and others involved in public health programmes;
grassroots community leaders such as representatives of
nongovernmental organisations (NGOs) and community-
based organizations (CBOs) implementing HIV-prevention,
care, and treatment programmes for people living with
HIV, religious leaders, and other community group leaders
(youth group leaders, community advocates, tertiary
institutions); and other stakeholders such as journalists
and religious leaders.
Participants recruited for the FGDs were representatives
of NGO and CBO groups implementing HIV-prevention,
care, and treatment programmes for people living with
HIV, health care workers, people living with HIV, serodis-
cordant couples, and key affected populations (MSM,Table 1 Telephone interview questions discussing the propos
No. Questiona
1 Have you heard of PrEP before now?
2 What do you know about PrEP?
3 How did you learn about PrEP?
4 Do you think there is any potential positive outcome if Nigeria include
5 If at the end of the extensive community consultation process there is
community do you think should be targeted during the pilot project a
6 Do you think we will encounter challenges when discussing PrEP with re
7 Do you think we will encounter challenges when discussing PrEP with co
8 Do you think we will encounter challenges discussing PrEP with PLHIV
9 Do you think we will encounter challenges discussing PrEP with the co
perspective? How do you think we can address this challenge?
10 Do you think Nigeria may face challenges in the implementation of Pr
your response? How do you think we can address this challenge?
11 Finally, is there anything else you would like to share with me about P
aFor questions 1, 4, and 6–10, participants responded as follows: yes, no, or no resp
permitted to provide additional comments.
No., number; PrEP, pre-exposure prophylaxis; PLHIV, people living with HIV.FSW, and PWID). Participation in the online survey was
open to all interested persons worldwide.
Data collection
Telephone interviews
A list of 238 persons working in the HIV and AIDS field
as researchers, ethicists, journalists, implementing partners,
development partners, policymakers, and health care
providers was generated from the NACA programme
office. Everyone on the mailing list was emailed brief
background information on PrEP and a request to
participate in a telephone interview by sharing their
telephone number and a convenient date and time for
the interview. Quantitative and qualitative data were
collected during the interview using a guide comprising 11
questions. The second, third, fifth, and eleventh questions
were open-ended to determine personal opinions and
perspectives on PrEP including thoughts, concerns, and
suggestions for implementation of a PrEP demonstration
project. Respondents had the option to comment and
further discuss any of the seven close-ended questions.
Interviewers were also free to further explore any
comments made by respondents during the telephone
interview. The topics covered during the interview included
the knowledge about PrEP, suggested target groups for the
PrEP clinical study, potential positive outcomes of PrEP,
barriers to PrEP access, and perceived challenges to PrEP
use. Table 1 summarizes the checklist and open-ended
question asked of respondents.
In-depth interviews
A total 111 IDIs were conducted. IDIs allowed exploration
of issues raised during the telephone interviews from aed PrEP demonstration project
s PrEP as part of its HIV-prevention package? What are your concerns?
consensus that PrEP should be implemented in Nigeria, which
nd why?
ligious leaders? Why? How do you think we can address this challenge?
mmunity leaders? Why? How do you think we can address this challenge?
? Why? How do you think we can address this challenge?
mmunity at large? Please could you explain the reason for your
EP as a HIV-prevention method? Please could you explain the reasons for
rEP such as your thoughts, suggestions, queries, concerns, and advice?
onse. Questions 2, 3, 5, and 11 were open-ended, and respondents were
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riences, opinions, and feelings regarding sensitive topics
and specific, relevant personal events. A semi-structured
guide was used to explore issues including the appropriate
target populations for PrEP use, PrEP messaging to target
populations and the general public, public policy required
to support PrEP interventions, PrEP intervention manage-
ment and decision-making, integration of PrEP into existing
HIV-prevention programmes, and building the capacity for
PrEP rollout. Interviews were conducted with public health
officials, national- and state-level policy makers, health
care providers and administrators, HIV development and
implementing partners, religious leaders, researchers, and
ethicists. Written consent was obtained from for all
participants except for one participant, who initially
preferred to give verbal consent and later signed the inter-
view transcript confirming that it was duly representative
of what was discussed during the interview.
Focus group discussions
Thirteen FGD transcripts were analysed. The FGDs
were conducted with relevant stakeholders who will
be directly or indirectly affected by a PrEP programme.
Four FGDs were each held in Benue, Edo, and Cross River
States and one FGD in Abuja. In each state, the first FGD
included key populations, namely MSM, male and female
sex workers, and PWID; the second FGD included health
care providers; the third included serodiscordant couples
and people living with HI;, and the fourth FGD included
representatives from HIV programmes and key community
gatekeepers such as religious leaders and journalists. The
size of each FGD ranged between six and 12 persons. The
sole FGD in Abuja included representatives from HIV
programmes and key community gatekeepers.
The FGD queried respondents on appropriate target
populations for PrEP; logistical barriers to PrEP access,
possible facilitators of PrEP access, and requisites for
PrEP use; cultural barriers, facilitators, and requisites for
using PrEP; and the benefits and appropriate costs for
PrEP. The FGDs used case scenarios to elicit discussion.
Before participating in the FGD, each individual gave
written consent for study participation after details of
the study were explained. Participants were allowed to
ask clarifying questions. Refreshments were provided
during the FGD, and participants were paid $12.50 each
as transportation reimbursement.
Online survey
The online survey explored public opinions on potential
target groups for a PrEP demonstration study in Nigeria,
reasons for the choices, potential positive outcomes of
PrEP, barriers and challenges to PrEP access, and means
to address these challenges. The online survey tool was
adapted from the telephone interview checklist. Question5 on the original checklist shown in Table 1 was expanded
into 12 sub-questions (Table 2).
The online survey was administered by the following
organizations: the New HIV Vaccine and Microbicide
Advocacy Society listserv, which is a forum providing
information on biomedical HIV-prevention research and
development to 5,432 subscribers; International Rectal
Microbicide Advocacy listserv, a forum providing
information on biomedical HIV-prevention research
and development focused on MSM and transgender
issues to approximately 1,200 subscribers; Project Africa
for Rectal Microbicide, a forum providing information
regarding rectal microbicide research and development to
53 subscribers; and the Journalists Against AIDS listserv, a
listserv distributed to over 2,000 persons and groups
participating in the HIV response. The online survey
was conducted for 3 weeks.
A total 70 responses comprising 36 (51.4%) men, 31
(44.3%) women, and three (4.3%) participants of unidenti-
fied gender were received from the online survey. Only 63
(95.5%) respondents indicated their age as follows: two
(2.9%) participants were aged 20 to 24 years; 23 (32.9%)
were 25 years to 35 years; 21 (30.0%) were 35 years to
44 years; 16 (22.9%) were 45 years to 64 years; and five
(7.1%) were aged 55 years to 64 years. Respondents were
from France, Nigeria, the United States, Australia, Congo,
Canada, Ghana, and Ethiopia. They included persons
working in academia, NGOs, CBOs, faith-based organiza-
tions, donor agencies, bilateral and multilateral partners,
and the private sector. Fifteen (21.4%) respondents did
not work in the HIV response sector. The data were
automatically summarized and compiled by the Google
Survey tool.
Consultative workshops
Nine serodiscordant couples from Cross River, Benue,
Abuja, and Edo States, and four representatives from
civil society organizations who were living with HIV
participated in the consultative workshop. The meeting
was conducted in English and Pidgin English because of
the low literacy levels of some participants. The objectives
of the meeting were to identify barriers, challenges, and
facilitators in implementing PrEP for serodiscordant
couples; develop strategies to address each barrier and
challenge; and cultivate strategies to educate peers on
daily PrEP use, including referring peers for screening
tests to determine if they qualify for daily PrEP and
encouraging compliance with quarterly safety and HIV
tests. Participants were divided into groups according to
their respective states in order to discuss state-specific
peculiarities. Group discussions were guided by a discus-
sion guide, and the same guide was used by all groups.
Discussions were then presented to the entire group for
further deliberation.
Table 2 Sub-questions forming the online survey following adaptation of the telephone interview guide
No. Questiona
5a The Nigeria HIV-prevention programme considers HIV-negative partners in serodiscordant relationships a high-risk group for HIV infection.
One of the many studies on PrEP showed a 75% reduction in the HIV incidence when a HIV-negative partner used PrEP. Would you consider
serodiscordant couples a priority target group for the PrEP demonstration project in Nigeria?
5b Please give the reason(s) for your response to question 5a.
5c The Nigeria HIV-prevention programme considers men who have sex with other men (MSM) a high-risk group for HIV infection. One of the
many studies on PrEP showed a 44% reduction in the HIV incidence when a HIV-negative MSM partner used PrEP. Would you consider MSM
a priority target group for the PrEP demonstration project in Nigeria?
5d Please give the reason(s) for your response to question 5c.
5e The Nigeria HIV-prevention programme considers male and female sex workers a high-risk group for HIV infection. No studies have been
conducted to evaluate the efficacy of PrEP in preventing HIV infection in this specific population. Would you consider male and female sex
workers a priority target group for the PrEP demonstration project in Nigeria?
5f Please give the reason(s) for your response to question 5e.
5 g The Nigeria HIV-prevention programme considers people who inject drugs (PWID) a high-risk group for HIV infection. One of the many studies
on PrEP showed a 49% reduction in the HIV incidence when a HIV-negative PWID used PrEP. Would you consider PWID a priority target group
for the PrEP demonstration project in Nigeria?
5 h Please the give reason(s) for your response to question 5 g.
5i The Nigeria HIV-prevention programme considers young women age 21 to 24 a high risk group for HIV infection. One of the many studies on
PrEP showed a 62% reduction in the HIV incidence in heterosexual couples. The study did not specifically focus on young women. However,
it showed that women can equally benefit from PrEP. Would you consider young women a priority target group for the PrEP demonstration
project in Nigeria?
5j Please give the reason(s) for your response to question 5i.
5 k If at the end of the extensive community consultation process there is consensus that PrEP should be implemented in Nigeria, which of the
target populations that you have identified could benefit from PrEP do you think the country should focus on during the pilot project?
5 l Please give the reason(s) for your response to question 5 k.
aQuestions in the online survey were designed based on the responses to question #5 in the initial telephone interview.
No., number; PrEP, pre-exposure prophylaxis; MSM, men who have sex with men; PWID, people who inject drugs.
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care providers, and representatives of the donor and imple-
menting community in Nigeria. The discussion focused on
methods to integrate PrEP into existing health services and
facilities, recommendations on ensuring PrEP access by the
PrEP demonstration project study population, and staffing
needs. Participants were divided into three groups to
discuss how PrEP delivery could be integrated with other
health services and facilities, facilitation of PrEP access, and
staffing issues for PrEP service delivery. Discussions were
then presented to the entire group for further deliberation.
Data analysis
The qualitative data included the following: transcripts
from telephone interviews, audio recorded IDI, and FGDs;
summary of the online survey results; and hand-written
notes (brief field notes, summary notes, debriefing
reports) from telephone interviews, IDIs, FGDs, and
consultative meetings. Data were inductively examined
using a content analytic approach to construct descriptive
categories. Responses corresponding to each study
objective were summarized and assigned to the descriptive
categories, and the categories were further examined to
identify general themes and broad concepts. The analytic
process began by completely reading the field notes
and transcripts to identify content related to the studyobjectives. Relevant quotes were retrieved from transcripts.
Results were compared and linkages made between these
various data sources allowing for confirmation, corrobor-
ation, and validation of study results through a triangula-
tion process. Findings across sites were compared, and
differences or similarities in the responses were explored
from various social, economic, and geographical contexts.
Ethical approval
This study was approved by the Nigerian Institute of
Medical Research Health Research Ethics Committee. The
study was conducted in full compliance with the approved
protocol. All staff, researchers, and field workers engaged
in this study were trained on research ethics emphasizing
the importance of informed consent and confidentiality.
No names or personal identifiers were recorded on
any study instruments. All study-related information
was stored securely and centrally at the NACA.
Results
Appropriate target groups for a PrEP demonstration
project in Nigeria
Suggestions on appropriate target populations for the
proposed PrEP demonstration project in Nigeria were
elicited through the telephone interviews, IDI, and
online survey.
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Forty-three (38.1%) respondents in the telephone interview
prioritized HIV serodiscordant couples for PrEP access in
the proposed demonstration project. One reason cited for
prioritizing serodiscordant couples was because HIV pre-
vention for the HIV-negative partner through condom use
was considered a barrier to procreation; PrEP would
assuage this concern while reducing the risk of HIV
infection. Several respondents noted these concerns in
the telephone interviews as follows:
“In marriage where one partner is HIV+ and the other
is not, there is no way we can say they should not have
sex. We already know the problems we have with
condom use, because it is perceived as a sort of barrier
in sexual acts. Women often have to negotiate with
their partners when they are the ones without the
virus. PrEP is actually easier to use for them because
it can just be taken before meeting with their partners.
It is also likely to give a sense of responsibility
on the part of the HIV+ male partners”.
(Telephone interview respondent)
“It will give the serodiscordant couples ‘hope’ and
increase the level of people disclosing status. And
probably improve adherence”. (Telephone interview
respondent)
Eighteen (15.9%) respondents in the telephone interview
prioritized key affected populations, often referred to
as the most-at-risk populations (MARPs) in the
national HIV response in Nigeria, for access to PrEP
in the proposed for the demonstration project. Reasons
cited for prioritizing MARPs included the need to target a
small defined population in the pilot study and national
epidemiological data showing that 10% of new infections
occur in MARPs. This was stated by two respondents as
follows:
“For the MARPs, especially the FSWs, it can be of
great help. They can use it 24 hours before sexual
acts and it can help limit the prevalence”.
(Telephone interview respondent)
“If PrEP is adopted, MARPS should be the target
community; a small population is advisable in a pilot
study”. (Telephone interview respondent)
Individual in-depth interviews
Of 111 total IDI participants, 106 suggested specific popu-
lations; the majority of respondents (56%) recommended
serodiscordant couples as the target population for the
proposed PrEP demonstration study. As stated by two
interviewees:“I think the first group for me [is] the partners of those
who are infected with HIV, in other words the
serodiscordant couples”. (IDI respondent)
“For one, I think the population we should think about
[target] is the high-risk groups, especially the discordant
partners”. (IDI respondent)
One reason given for prioritizing PrEP access to this
population was that serodiscordant couples were consid-
ered at high risk of HIV infection. Another reason was the
ease in working with serodiscordant couples, which helps
address the challenges with adherence to the PrEP regimen.
Several respondents expressed this concern during the
extended interviews:
“We find HIV serodiscordance among partners of
those who are HIV-positive is quite high; I cannot give
specific data but I would say it is considerably high”.
(IDI respondent)
“…married people are more reasonable and stable,
unlike the youths”. (IDI respondent)
“If we can get people to embrace it, like the discordant
partners, that is a group I think we should expect good
success with because they are committed and they are
together and they know after counselling that they will
really need this drug to stay protected, so they will
show strong commitment”. (IDI respondent)
Online survey
Sixty-one (92.4%) online survey respondents prioritised the
use of PrEP by serodiscordant couples, and 29 (43.9%) their
enrolment in the PrEP demonstration study. HIV-negative
partners in serodiscordant relationships were considered to
be at high risk for HIV infection, a risk that could be
reduced by PrEP use. The following quotes represent
some of the reasons provided:
“The serodiscordant couples are already living with a
HIV-positive partner and are at high risk of contacting
the HIV virus”. (Online survey respondent)
“PrEP will help in mutual adherence for both
partners and the success can be predicted”.
(Online survey respondent)
Male and female sex workers
Male and female sex workers received the second highest
consideration for PrEP access. Fifty-two (78.8%) online
survey respondents endorsed access to PrEP for male
and female sex workers, and 15 (22.7%) respondents
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stration project. However, recruiting male and female sex
workers for the proposed PrEP demonstration study may
prove challenging owing to poor retention caused by their
high mobility.
Men who have sex with men
Forty-nine (74.2%) online survey respondents endorsed
PrEP access in MSM, but only seven (10.6%) respondents
prioritized their enrolment in the PrEP demonstration
project. In general, respondents felt that MSM should not
be prioritized for PrEP access because the social and
cultural environment in Nigeria stigmatises and does not
support MSM, despite their heightened risk for HIV
infection. One reason identified for prioritizing access
to PrEP by MSM was the need to achieve the national goal
of preventing new HIV infection irrespective of sexual
orientation. However, the criminalization of same sex prac-
tices in Nigeria makes PrEP access by MSM challenging, as
stated by one respondent:
“As an epidemiological group, MSM face higher risks
than others. The political climate in Nigeria, with the
recent anti-gay law, might however be a problem for
targeting MSM in research, and it is important that
research does not increase risk of violence or stigma.
For this reason MSM might need to be targeted using
a euphemism, such as “men at increased risk of HIV” and
allowed to self-identify as “high risk” in that way rather
than as an MSM”. (Online survey respondent)
People who inject drugs
Forty-six (69.7%) respondents on the online survey
endorsed PrEP access by PWID, but only one (1.5%)
respondent prioritized their enrolment in the PrEP
demonstration project. Concerns raised included the
need to provide clean needles for study participants,
which was considered to encourage intravenous drug
use. Also, the PWID population in Nigeria is considerably
smaller than other populations at high risk for HIV,
such as serodiscordant couples, male and female sex
workers, and MSM. This preference was expressed by
one respondent as follows:
“I would still rate them after discordant couples,
MSM, sex workers because the percentage of PWID
in Nigeria is not as high as the other rates”.
(Online survey respondent)
Young women aged 21–24 years
Forty-five (68.2%) online survey respondents endorsed
young women’s access to PrEP, and 11 (13.6%) prioritized
their enrolment in the PrEP demonstration project.
Reasons cited for their consideration for study enrolmentincluded being sexually active, being at high risk for HIV
infection, their vulnerability to sexual abuse, and their
marginal ability to negotiate condom use. This concern
was raised by one respondent as follows:
“More women are HIV-positive in Nigeria. Many women
sell sex for family up -keeps, hence it is imperative that
this group be considered. (Online survey respondent)
Other target populations
Other target populations for a PrEP demonstration project
in Nigeria identified through the telephone interviews and
IDI were health care workers, uniformed service men, and
residents of states with a high HIV prevalence. One
respondent recommended individuals in regions facing
conflict as a target population as follows:
“The focus should be especially in the southeast, south,
southwest and north-central geopolitical zones of the
country where, the incidence of rape and internal
displacement is high. People are more vulnerable as
a result of rape.” (Telephone interview respondent)
Community interest and perception about PrEP as a
HIV-prevention tool
The level of interest and support for PrEP in the general
community as perceived by the respondents was dis-
cussed in the telephone interviews, IDI, and online
survey.
Eighty-four (74.3%) of the telephone interview respon-
dents and 62 (93.9%) of the online survey respondents felt
that the PrEP use would provide additional benefits for
the country’s HIV response programme by helping to
reduce the HIV incidence, increase lifespan, and preserve
long-term relationships in serodiscordant couples. Other
potential gains included growth of HIV prevention pro-
grammes in key affected populations and a greater range
of available HIV-prevention options, as stated by several
survey respondents:
“PrEP will provide most men having sex with men
(MSM) who do not use any prevention method
and who also have heterosexual sex with others
in the general population some protection”.
(Online survey respondent)
“PrEP will afford serodiscordant couples a new beauty
to life as they will be able to live a reproductive life,
protect unborn children and have peace of mind”.
(Online survey respondent)
“PrEP offers a potential advantage over male and
female condom use, which requires partner consent”.
(Online survey respondent)
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programme will only be successful if the government
can ensure its sustained access. Concerns about the
level of poverty, heavy workload for health personnel, and
the effect of these factors on the efficacy of a proposed
PrEP programme were expressed; the success of the PrEP
programme therefore, seemed daunting. To ensure the sus-
tainability of a PrEP programme, the Nigerian government
must develop a plan that addresses the capacity needs of
the health workforce, creates awareness of the program in
the community, avoids depending solely on development
partners for programme implementation, and invests in the
local manufacture of Truvada (a PrEP drug) to reduce its
cost. Integrating PrEP into the current HIV-prevention
programme and decentralizing PrEP delivery to improve
access and coverage are paramount.
Respondents identified several potential community
concerns about PrEP. There was overwhelming concern
that religious organizations might be unsupportive because
promoting PrEP would be seen as promoting sexual
promiscuity. However, most respondents believed that
with adequate information and sensitization, this challenge
could be addressed.
Other concerns expressed included a likely increase in
risky sexual behaviours, misconceptions and misinterpre-
tations about PrEP use because of low literacy levels,
stigma associated with PrEP use, poor adherence with
daily dosing by healthy individuals, and the fear of
side-effects potentially decreasing adherence to the PrEP
regimen. Respondents stated that:
“We even have to be careful on how we are going to
implement it so that people don’t abuse it. People may
just be having sex without condoms and will take
Truvada instead … We don’t want PrEP to be abused
the way emergency contraception such as “Postinol”
have been abused”. (Telephone interview respondent)
“[to be] seen taking drugs all the time could cause fear
and stigma” and “people might label them for going to
collect HIV drugs”. (IDI study participants)
Community leaders and members need to be informed of
and involved in the design and implementation of the PrEP
demonstration project, which would promote acceptance
and ownership of the programme by communities. This
requires giving appropriate and clear information about
PrEP to communities at dialogue sessions, and through
mass public education and sensitization using mass media.
Many (53.0%) online survey respondents did not anticipate
any major challenges in engaging community leaders in a
dialogue about PrEP. In Cross River and Edo States, IDI
respondents noted that enactment of a local anti-stigma
law would limit stigma and discrimination.Communicating about PrEP with different stakeholders
Various stakeholders identified the need to effectively
engage the electronic and print media in public education
about PrEP. Prime time periods on electronic media
could be used to disseminate information. Respondents
from the Abuja metropolis recommended using social
media such as Facebook, blogs, and Twitter to create
awareness about PrEP among young people. Some
suggested using euphemistic names such as “Touch
and Go”, “Fame”, “Family Vitamins”, and “Hope” for PrEP
because of the potential stigma that may be associated
with PrEP use.
Concerns about PrEP use by serodiscordant couples
Stigma was identified as a major concern and poten-
tial barrier for PrEP acceptance and use by serodis-
cordant couples. Identification as someone needing
PrEP and the need for repeated hospital visits were
considered stigmatizing and suggestive of HIV infec-
tion. Other concerns raised were: challenges in taking
drugs when not ill, fear of blood samples being used
for nefarious purposes, general apathy towards medical
examinations, side-effects from ARV therapy use, poten-
tial for drug resistance arising from drug unavailability
and nonadherence, increased HIV risk behaviour, coping
with frequent hospital visits for blood tests, drug refills,
and counselling, and the long-term sustainability of the
programme.
Serodiscordant couples also identified the need for the
proposed PrEP demonstration project to accommodate
the social context and realities of their lives. Typically,
the index partner is an HIV-positive woman diagnosed
during pregnancy. A diagnosis of HIV serodiscordance
often leads to a breakdown of the marital relationship.
The PrEP programme would therefore need to provide
counselling and guidance to beneficiaries. These sessions
could address marital issues among others. Support groups
for serodiscordant couples would be a veritable means to
address this potential challenge.
Innovative HIV testing strategies are also required in
order to recruit couples comprising an HIV-negative
woman and HIV-positive man. Incentives for HIV testing
may promote agreement to testing by men.
One participant in the consultative meeting with sero-
discordant couples noted a potential challenge that may
arise in encouraging PrEP use, especially by HIV-negative
men in serodiscordant relationships, namely that the
HIV-negative partner may balk at the PrEP regimen
due to their partner’s infection, as expressed in
through the response: “Why should I take drugs for
your infection?” There was also concern on the poor
attitude of health care workers towards PrEP users,
including breaching confidentiality and stigma expressed
by health care workers.
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demonstration project
Suggestions for the design and implementation of a
PrEP demonstration project in Nigeria were elicited
through the FGDs and consultative meetings. Respondents
recommended that PrEP be prescribed free of charge. One
reason cited was the need to forestall the sale of counterfeit
drugs. However, if drugs must be sold, the suggested price
ranged between 50 and 2,000 naira per prescription.
Another concern raised by a respondent on the online
survey was that the Nigeria HIV programme will face
two different markets of circulation: one (private) for
condoms and another (social) for PrEP. A plan is
needed to contain these multiple programmes including
the development of new HIV-prevention campaigns.
Respondents during the FGD recommended that PrEP
drugs be prescribed and dispensed by qualified health
workers, particularly doctors, pharmacists, and pharmacy
assistants, in both public and private health facilities.
Policy makers and programmers at the consultative
meeting for policy makers concurred on the need to
decentralize service delivery for PrEP; baseline HIV testing
and initial PrEP treatment could be done at tertiary and
secondary health facilities, while drugs could be dispensed
at primary health centres. In addition, respondents recom-
mended that PrEP services be centralized to the initiating
tertiary/secondary facility for the first three months, which
is a critical period in the care programme. Laboratory
evaluations should also be performed every 6 months at
the initiating facility. Drug refills and three-monthly HIV
Counselling and Testing should be conducted at private
hospitals and primary health care centres linked to the
initiating facilities, also referred to as satellite centres. All
health care workers at the central and satellite centres
should be regularly trained on adherence counselling and
ethical health care delivery.
State-specific service delivery models were identified
during the consultative meetings for serodiscordant
couples and policy makers. For Cross-River State, the
serodiscordant couples preferred that PrEP delivery be
integrated into routine outpatient care. This, they
opined, should reduce potential stigma. In Benue and
Edo States however, serodiscordant couples preferred
that PrEP delivery be integrated into existing ART
programme in order to increase the opportunities for
spouses receiving highly-active antiretroviral therapy
to pick up PrEP refills for their HIV-negative spouses.
Discussion
This study shows that there is high public interest and
support for the use of PrEP as part of the HIV-prevention
armamentarium in Nigeria. The respondents prioritized
HIV serodiscordant couples for PrEP access in a planned
PrEP demonstration project in Nigeria for several reasonsincluding the challenges faced by couples in continual
condom use, the increased prospect for procreation, and
the enhanced ability to reduce marital discord. However,
several challenges were identified for PrEP use and access,
especially the potential for stigma associated with ARV
use and the increased likelihood of index partners being
women, as most serodiscordant couples are identified
through screening for HIV infection in women attending
antenatal clinics. For a male dominated society such
as Nigeria, this has significant implications for the
uptake and use of PrEP by HIV-negative male partners in
serodiscordant relationships.
The design of an HIV-prevention package that includes
PrEP for HIV serodiscordant couples in Nigeria is apt. A
high incidence rate of 1.2 per 100 person-years among
serodiscordant couples was reported in a highly controlled
clinical trial where aggressive viral suppression was pro-
vided for the index partner [17]. Approximately 20% of
seroconversion events in serodiscordant couples are
caused by a sexual partner other than the index partner
[18]. For many couples, consistent condom use can be
challenging especially in a culture where having children
is of great importance [18]. Several reports show that
serodiscordant couples increasingly have multiple sexual
partners over life and often indulge in unprotected sexual
intercourse [19]. Unprotected sex may also occur in
an attempt to conceive, further increasing the risk for
seroconversion even when the sexual partner is viro-
logically suppressed [20].
Stigma was identified as a potential barrier for PrEP
use and discrimination a potential consequence of its
use. This is likely a reflection ofs the stigma associated
with ARV use for management of HIV infection. Stigma
has long been identified as a deterrent for uptake of
HCT services [21], agreement to antiretroviral therapy [22],
and adherence to the ARV drug regimen [23]. Education
about the possible use of ART for HIV prevention may
broaden the public’s knowledge and understanding of
PrEP. However, the potential for public education to stem
reluctance in communities where ART is stigmatised may
be limited. The potential for stigma associated with PrEP
use has been previously identified [24,25] and is a real
concern in people using PrEP [24]. It is a recognized cause
of low adherence and discontinuation of therapy [26]. The
PrEP demonstration project should explore strategies
for communicating about PrEP in ways that do not
perpetuate stigma. For example, the PrEP demonstration
project could be open to all persons who perceive
themselves at high risk of HIV infection. Recruitment
can then be limited to those at highest risk for HIV
infection, especially those who have HIV-positive sex
partners. PrEP users must be empowered to prevent
stigma from family, friends, and significant others.
Information about PrEP should also be included in stigma
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should enable people to assess their beliefs and address the
underlying prejudices that may affect decision making and
actions.
Beyond stigma, the feasibility of covert use of PrEP by
women may also be limited by the cultural contexts that
define male–female relationships. Many persons in
Africa do not support covert use of PrEP products
(whether pills, gel, or a potential injectable), except
perhaps with casual or paying partners. While this study
did not explore the feasibility of covert use of pills as PrEP
for HIV prevention by women, it is important that this
consideration be factored into the design and implementa-
tion of the PrEP demonstration programme.
A PrEP study for serodiscordant couples requires that
couples know their HIV status. Where individuals
disclose their HIV-positive status to their partner,
partner support is a well-known motivator for ART
adherence [28,29]. However, many individuals never
disclose their HIV status to their partners [29] for fear of
partner violence, stigma, and loss of economic support,
among other reasons [29]. Oftentimes, serodiscordance is
identified in the antenatal clinic during couple testing.
This implies that the majority of participants in a PrEP
demonstration project will be men. In a male dominated
society such as Nigeria, HIV-negative male partners who
use PrEP may face stigma owing to HIV infection of the
female partner. Many participants may balk at facing
this stigma or taking medication owing to their partner’s
infection. The reality of this challenge moves the discussion
of PrEP access and use in serodiscordant relationships well
beyond the biomedical sphere. The realities of individuals
living with HIV and the challenges of serodiscordance
must be considered in the design and implementation
of PrEP access programmes. Marital counselling may
therefore be required in the design of the PrEP demon-
stration project as highlighted by the respondents in the
consultative workshops.
There were concerns raised about resistance resulting
from drug unavailability and nonadherence to therapy.
The development of resistance to ARVs used as PrEP is
possible. In trials where monitoring and follow-up of
participants is strict and regimented, the number of
patients who developed resistance to PrEP medication
was extremely low; two participants enrolled in an iPrEx
study with undetected, seronegative acute HIV infection
who were randomized to receive daily oral tenofovir-
emtricitabine developed resistance to emtricitabine [30].
A similar case was also reported in the TDF2 study [30].
When HIV-positive individuals do not adhere to therapy,
resistance may arise and this is a challenge. However,
the potential for resistance in PrEP is more complex, as
poor compliance would more likely lead to HIV infection
[28]. Increased exposure to partially suppressive ARVsraises the risk of selecting resistance mutation, which may
compromise the preferred regimen should the individual
seroconvert. Furthermore, it may impact the efficacy of a
second-line antiretroviral therapy regimen in Nigeria [28].
At a population level, PrEP could lead to drug resistance
and limit access to ARV beyond the second-line regimen
[30,31]. The National PrEP demonstration project should
consider the immediate and long-term implications of
participants developing resistance to the PrEP regimen
and strategies to reduce or eliminate the potential for
resistance during real life access.
The concern expressed over revamping the HIV-
prevention campaign is real. Most recently, the US
Centers for Disease Control and Prevention, in response
to the campaign by the HIV Prevention Justice Alliance,
agreed with the need to avoid the term “unprotected sex”
and instead specifically refer to condom use. This is
critical because a person on ART who is virologically
suppressed can actually have safe sex even without
using a condom [32]. The cost associated with revising
documents and educational campaigns may be enormous,
but is necessary in light of emerging scientific and prag-
matic evidence. The national PrEP demonstration project
will need to assess the impact of these public educational
messages on the general understanding of ARV use in
reducing the risk for sexual transmission of HIV.
While HIV serodiscordant couples are at high risk for
HIV infection, especially in Nigeria where child conception
following marital union is a priority, there are other
populations in Nigeria who are also at high risk of
HIV infection, as the present study acknowledges. We
however cannot readily identify reasons why the access of
HIV serodiscordant couples to PrEP as prioritized over
access to PrEP by other high risk populations. Several
responses alluded to the unsupportive legislative environ-
ment that makes working with MARPs challenging. The
lessons learned during implementation of the current
national HIV response programme for key affected
populations in Nigeria [33,34] will inform the design
of a PrEP access programme for MSM, FSW, and PWID
as it is scaled up to ensure wider PrEP access to multiple
populations in Nigeria.
Conclusion
It is clear that there will be challenges associated with
the acceptance of PrEP by HIV serodiscordant couples
in Nigeria, but many of the challenges identified are
surmountable. However, much depends on the actions
taken by multiple players including the capacity to conduct
couple counselling and identify serodiscordant couples,
motivation of HIV-negative male partners to use PrEP,
adherence to the PrEP regimen and HIV monitoring, and
effective public education addressing stigma. Concerns
about the risk of increased resistance and the potential loss
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sidered. Therefore, as one of its goals, the PrEP demon-
stration project in Nigeria should determine which HIV
serodiscordant couples are most likely to benefit from the
intervention and most likely to comply with a regimented
care plan incorporating both PrEP and frequent HIV
testing [20]. It should also identify how best to optimize
drug adherence among PrEP recipients and intervene if
the drugs are not taken properly [31].
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